Oportuzumab monatox

Drug Profile

Oportuzumab monatox

Alternative Names: Anti-ECAM exotoxin A fusion protein; Proxinium; VB-4847; VB-845; VB4-845; Vicinium

Latest Information Update: 16 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Zurich
  • Developer Eleven Biotherapeutics; Viventia Biotechnologies
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bladder cancer
  • Phase II/III Head and neck cancer
  • No development reported Liver cancer; Ovarian cancer

Most Recent Events

  • 07 Jun 2017 Eleven therapeutics, National Cancer Institute and AstraZeneca agree to co-develop ViciniumTM in combination with durvalumab for the treatment of non-muscle invasive bladder cancer
  • 07 Jun 2017 Eleven Biotherapeutics in collaboration with National Cancer Institute and AstraZeneca plan a phase I trial for the treatment of Bladder cancer (Combination therapy) in USA
  • 03 Apr 2017 Pharmacodynamics data from preclinical studies in Cancer released by Eleven Biotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top